CTIS2024-515551-38-00招募中1 期
21 SARC 04
Oncopole Claudius Regaud0 个研究点目标入组 20 人开始时间: 2024年7月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced MelanomaMetastatic MelanomaMedDRA version: 20.0Level: LLTClassification code: 10027481Term: Metastatic melanoma Class: 10029104CTIS2024-511949-19-00Sairopa B.V.44
进行中（未招募）
1 期
Phase I/II study assessing radioligand therapy (RLT) using 177Lu-PentixaTher for relapsed/refractory CXCR4+ acute leukemia.Acute LeukemiaCTIS2022-501019-15-00Centre Hospitalier Universitaire De Nantes21
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
进行中（未招募）
1 期
Double-blind, randomized, placebo-controlled, pilot study to evaluate the safety, tolerability and efficacy of two doses of a conditioned medium from a co-culture of M2-macrophages and mesenchymal cells (PRS CK STORM) in the prevention of COVID-19-associated cytokine stormSARS-CoV-2 infectionMedDRA version: 23.0Level: LLTClassification code: 10084272Term: SARS-CoV-2 infection Class: 10021881CTIS2023-507700-32-00Peaches Biotech S.L.50
尚未招募
不适用
Premarket study to assess safety and performance of the Orion Magnetic Localization System for breast cancerBreast CancerNL-OMON24152Sirius Medical Systems B.V.30